BioSpace News Archive

Paragon Therapeutics announced today that the third company founded based on assets generated by Paragon, Oruka Therapeutics (“Oruka”), has entered into a definitive agreement with ARCA biopharma to combine the companies in an all-stock transaction.

Verismo Therapeutics today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its Phase 1 clinical trial of SynKIR™-310, for the treatment of relapsed/refractory (r/r) B-cell Non-Hodgkin Lymphomas (B-cell NHL), including Diffuse Large B Cell lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL).

Equillium, Inc. today announced that on April 1, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 10,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan.

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacodynamic effects of ALTO-203 in MDD patients as well as assess its safety, tolerability, and pharmacokinetics.

HemoSonics, a medical device company focused on acute bleeding management, today announced it has received Special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded use of arterial blood samples with its Quantra QStat® Cartridge.

The Cystic Fibrosis Foundation is investing up to $8.5 million in additional funds in SpliSense to continue clinical trials for its inhaled antisense oligonucleotide (ASO) drug for people with cystic fibrosis.

Prilenia Therapeutics B.V. today announced the appointment of Dr. Jina Swartz, M.D. Ph.D., as its first Chief Medical Officer (CMO).

Guardant Health, Inc. today announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10 in San Diego.

Lisata Therapeutics, Inc. today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will participate in the following events in April.

In conventional practice, a blood culture report wouldn’t be available until 18 to 72 hours later, rendering it non-feasible to facilitate rapid response.